Citations

Clear

69 citation(s) found for "Feagan, Brian".

DOP56 Histologic disease activity correlates with endoscopic severity in patients with moderate to severe Crohn’s Disease
Reinisch, Walter , Protić, Marijana , Chan, Lai Shan, Pollack, P, Feagan, Brian G. , Pai, Rish K. , Reinisch, Walter , Hertogh, Gert D. , Magro, Fernando , Harpaz, Noam

Mayo Clinic

Journal of Crohn's and Colitis | January 21, 2022 | Volume: 16 | Issue: Supplement_1 | Pages: i103-i105

10.1093/ecco-jcc/jjab232.095 Get It

Abstract Background The role of histopathology evaluation in Crohn’s disease (CD) is not precisely defined. Due to the heterogeneity of phenotypes, the discontinuity of distribution, and the transmural nature of inflammation, the interpretation of histologic outcomes is complex. To analyze how histology relates to established outcomes in CD, we examined association between histologic and endoscopic disease activity measured by frequently used scores (simple endoscopic score for Crohn’s disease [SES-CD], Robarts histopathology index [RHI], global histological activity score [GHAS]) and the association between histologic or endoscopic severity with inflammatory biomarkers in a cohort of patients with moderate-to-severe CD. Methods Patients (N=191) who were enrolled in a phase 2 randomized clinical trial (NCT02891226) in patients with moderate-to-severe CD were assessed at baseline (BL) for endoscopic disease location and severity as measured by SES-CD. Biopsies were obtained during BL endoscopy from the edge of the ulcers and the most inflamed mucosa in terminal ileum and 4 colonic segments (ascending, transverse, descending, rectum; N=10/patient, 2 per location with the more severe score used), and scored by central readers blind to study treatment, timepoint, and response status using RHI and both modified and active GHAS (mGHAS: Q1, 3, 4, 5, 6; aGHAS: Q1, 4, 5, 6; see Fig. 1). Inflammatory biomarkers included fCLP and CRP; log-transformed values are used. Linear correlations between measures were determined using Pearson correlation coefficients (PCC) as exploratory analyses. Nominal p values are presented. Results SES-CD correlated well with all 3 histologic measures examined (Fig. 1). While both fCLP and CRP correlated more closely with endoscopy than with histologic measures, fCLP had higher correlation with each histologic measure than CRP (Fig. 2). 64% of patients had the same disease location at BL when measured by endoscopy or histology. Patients with endoscopic colonic disease displayed histologic ileal involvement in up to 20% of cases, while 13% of patients with endoscopic ileal disease demonstrated histologic colonic involvement (Table 1). Conclusion Although histologic disease activity in CD, as determined by 3 different measures, correlates well with endoscopic assessment of disease, histologic involvement provides complementary information on disease distribution and extension. Further analyses are required to understand the additive role of mucosal histology in CD.
Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis
Levesque, Barrett G., Feagan, Brian G. , Jucov, Alina , Bhandari, Bal Raj, Pai, Rish K. , Meadows, Kristen Taylor, Bruey, Jean‐Marie, Olson, Allan, Osterhout, Robin , Biene, Courtney Van, Ford, Julia, Aranda, Richard, Raghupathi, Kartik, Sandborn, William J. , Danese, Silvio , Sandborn, W J , Danese, Silvio , Kirby, Brian J. , Osterhout, Robin E.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | January 11, 2022 | Volume: 55 | Issue: 4 | Pages: 401-411

10.1111/apt.16753 | PMID 35014040 Get It

SummaryBackgroundEpithelial barrier dysfunction contributes to a dysregulated intestinal immune response in ulcerative colitis (UC). GB004 is an orally administered, small molecule, gut‐targeted stabiliser of hypoxia‐inducible factor‐1α, a transcription factor with protective roles at the epithelial layer of the inflamed gut.AimsTo evaluate safety, pharmacokinetics, pharmacodynamics and efficacy of GB004 in patients with active UC.MethodsThis double‐blind, placebo‐controlled study randomised patients 2:1 to receive an oral solution of GB004 120 mg or placebo once daily for 28 days. Eligible patients had a Robarts Histopathology Index score ≥4 with neutrophils in the epithelium, total Mayo Clinic score 3‐12, Mayo Clinic endoscopic subscore ≥1, and blood in the stool, despite treatment with 5‐aminosalicylates, corticosteroids or immunosuppressants.ResultsThirty‐four patients were randomised. GB004 120 mg for 28 days was generally well‐tolerated. Adverse events occurred in 27.3% (3/11) and 39.1% (9/23) of patients in the placebo and GB004 groups respectively. Nausea and dysgeusia were most commonly reported in the GB004 group (0% for placebo and 21.7% [5/23] and 13.0% [3/23] respectively for GB004). There were no treatment‐related serious adverse events or deaths. GB004 exhibited minimal accumulation, with higher colonic concentrations relative to plasma. Exploratory pharmacodynamic and efficacy analyses demonstrated GB004 target engagement and numerically higher proportions of patients achieving improvement in multiple measures of disease activity, respectively, at day 28 for GB004 compared to placebo.ConclusionResults from this phase 1b trial support evaluation of the full therapeutic potential of GB004 for the treatment of UC. A phase 2 study (NCT04556383) is ongoing. Clinicaltrials.gov NCT03860896.
Responsiveness of a Histologic Scoring System Compared With Peak Eosinophil Count in Eosinophilic Esophagitis
Ma, Christopher , Feagan, Brian G. , Guizzetti, Leonardo , Zou, Guangyong , McFarlane, Stefanie C., Shackelton, Lisa M. , Hirano, Ikuo , Rooij, Willemijn E. de , Pai, Rish K. , Dellon, Evan S. , Ma, C , Guizzetti, L , Zou, Guangyong , Jairath, Vipul , Collins, Margaret H. , Schaeffer, David F. , Bredenoord, Albert J.

Mayo Clinic

American Journal of Gastroenterology | November 19, 2021 | Volume: 117 | Issue: 2 | Pages: 264-271

10.14309/ajg.0000000000001571 | PMID 34797816 Get It

INTRODUCTION: The optimal instrument for assessing histologic disease activity in patients with eosinophilic esophagitis (EoE) is unclear. We assessed the responsiveness of the EoE Histologic Scoring System (EoE-HSS) when compared with that of the peak eosinophil count (PEC). METHODS: Histopathology slides were obtained from patients with EoE at baseline and after 8 weeks of treatment with swallowed topical budesonide or elimination diet. Two blinded gastrointestinal pathologists scored biopsies on the EoE-HSS, PEC, and 100-mm visual analog scale (VAS) of overall histologic severity. Change was defined as an improvement by ≥0.5 SD in baseline VAS. Responsiveness was quantified using the standardized effect size (SES) and the probability that the index distinguishes a patient with improvement from a patient without improvement, which is the area under the receiver operating characteristic curve (AUC). Longitudinal validity was assessed using Pearson correlations between changes in EoE-HSS and both PEC and VAS. RESULTS: The EoE-HSS grade (SES 2.18 [95% confidence interval, CI: 1.46–2.88]; AUC 0.73 [95% CI: 0.57–0.84]) and stage (SES 2.07 [95% CI: 1.37–2.77]; AUC 0.73 [95% CI: 0.58–0.84]) were highly responsive, similar to PEC (SES 1.44 [95% CI: 0.80–2.07]; AUC 0.73 [95% CI: 0.58–0.84]). The EoE-HSS grade and stage were more highly correlated with changes in VAS (grade 0.92 [95% CI: 0.86–0.95]; stage 0.89 [95% CI: 0.81–0.94]) than with changes in PEC (grade 0.74 [95% CI: 0.58–0.85]; stage 0.66 [95% CI: 0.47–0.80]). DISCUSSION: The EoE-HSS is highly responsive, performs similarly to PEC, and is better correlated with changes in overall histologic activity in patients with EoE.
PMO-30 Corticosteroid-free remission of ulcerative colitis with filgotinib maintenance therapy: post-hoc analysis of the SELECTION study
Morison, Ben, Vermeire, Séverine , Feagan, Brian, Yun, Chohee , Hsieh, Jeremy, Liu, Xiaopeng, Zhao, Sally, Moerch, Ulrik, Sandborn, William J. , Hibi∥, Toshifumi , Vermeire, Séverine , Loftus, Edward V.

Mayo Clinic

Posters | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A92.2-A92

10.1136/gutjnl-2021-bsg.169 Get It

S897 Impact of Mirikizumab Therapy on Histologic Measures of Intestinal Inflammation in a Phase 2 Study of Patients With Moderately- to Severely-Active Crohn’s Disease
Pai, Rish K. , Reinisch, Walter , Feagan, Brian G. , Agada, Noah , Pollack, Paul, Chan, Lai Shan, Protić, Marijana , Hertogh, Gert D. , Reinisch, Walter , Harpaz, Noam , Magro, Fernando

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S422-S423

10.14309/01.ajg.0000777120.59385.ef Get It

S772 Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn’s Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies
Ferrante, Marc , Baert, Filip , Feagan, Brian G. , Ran, Zhihua , D’Haens, Geert , Song, Alexandra , Neimark, Ezequiel, Liao, Xiaomei, Berg, Sofie, Wallace, Kori, Bossuyt, Peter , Danese, Silvio , Loftus, Edward V. , Panés, Julián , Peyrin‐Biroulet, Laurent , Armuzzi, Alessandro , Zhou, Qian , Panaccione, Remo

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S357-S358

10.14309/01.ajg.0000776620.39225.48 Get It

S754 Risankizumab as Induction Therapy in Patients with Moderately to Severely Active Crohn’s Disease Who Failed 1 vs >1 Prior Biologic Treatment: Results From the MOTIVATE Study
Dubinsky, Marla C. , Ferrante, Marc , Song, Alexandra , Liao, Xiaomei, Berg, Sofie, Duan, W. Rachel, Wallace, Kori, Feagan, Brian G. , Panaccione, Remo , Schreiber, Stefan , Peyrin‐Biroulet, Laurent , Loftus, Edward V. , Huang, Bidan

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S348-S348

10.14309/01.ajg.0000776548.94565.6c Get It

Development of antifibrotic therapy for stricturing Crohn’s disease: lessons from randomized trials in other fibrotic diseases
Lin, Sinan , Mao, Ren , Qian, Chenchen , Wang, Jie , Bruining, David H. , Feagan, Brian G. , Chen, Minhu , Rieder, Florian , Rieder, Florian , Bettenworth, Dominik , Li, Jiannan , Jairath, Vipul

Mayo Clinic

Physiological Reviews | September 27, 2021 | Volume: 102 | Issue: 2 | Pages: 605-652

10.1152/physrev.00005.2021 | PMID 34569264 Get It

Intestinal fibrosis is considered an inevitable complication of Crohn’s disease (CD) that results in symptoms of obstruction and stricture formation. Endoscopic or surgical treatment is required to treat the majority of patients. Progress in the management of stricturing CD is hampered by the lack of effective antifibrotic therapy; however, this situation is likely to change because of recent advances in other fibrotic diseases of the lung, liver, and skin. In this review, we summarize data from randomized controlled trials (RCTs) of antifibrotic therapies in these conditions. Multiple compounds have been tested for antifibrotic effects in other organs. According to their mechanisms, they were categorized into growth factor modulators, inflammation modulators, 5-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, intracellular enzymes and kinases, renin-angiotensin system (RAS) modulators, and others. From our review of the results from the clinical trials and discussion of their implications in the gastrointestinal tract, we have identified several molecular candidates that could serve as potential therapies for intestinal fibrosis in CD.
Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn’s Disease
Sandborn, William J. , Lewis, James D. , Panés, Julián , Loftus, Edward V. , D’Haens, Geert , Yu, Zhuqing , Lacerda, Ana P. , Pangan, Aileen L., Feagan, Brian G. , Loftus, Edward V , Panes, Julian , Lewis, James D , Huang, Bidan

Mayo Clinic

Journal of Crohn's and Colitis | September 20, 2021 | Volume: 16 | Issue: 3 | Pages: 444-451

10.1093/ecco-jcc/jjab161 | PMID 34546360 Get It

Abstract Background and Aims Patient-reported outcomes are recommended endpoints in Crohn’s disease [CD] trials. The association between patient-reported general well-being relative to symptoms of diarrhoea and abdominal pain [AP] in patients with moderate to severe CD was explored. Methods Patients from three randomized, placebo-controlled, double-blind adalimumab or upadacitinib studies with average daily very soft/liquid stool frequency [SF] ≥4 and/or AP score ≥2 at baseline were included. Using electronic diaries, patients reported general well-being [seven-point Likert scale; 1 = worst; 7 = best] in item 10 of the Inflammatory Bowel Disease Questionnaire [IBDQ]. Changes in well-being and clinical outcomes of SF and AP from baseline to week 12 or 16, and the relationship between well-being and clinical outcomes were evaluated using cumulative distribution function and probability density function curves. Results In total, 858 patients with CD were included [adalimumab, n = 695; upadacitinib, n = 163]. Patients who achieved clinical remission [SF ≤2.8, AP score ≤1.0, neither worse than baseline] were more likely than those not in clinical remission to report IBDQ item 10 response in the 6–7 group category but not IBDQ categories ≤5. Higher IBDQ score for item 10 [6–7] was associated with lower SF and AP score. Greater point increases in IBDQ item 10 were associated with a greater percentage decrease in clinical parameters; a ≥25–30% decrease in SF or AP was associated with a ≥1-point improvement in IBDQ. Conclusions An association between improvements in patient-reported general well-being and clinical remission/response was observed using outcomes of SF and AP, supporting the clinical remission/response endpoint definitions used in clinical studies of CD. Clinical Trial Registrations [ClinicalTrials.gov]: NCT00077779 [CHARM]; NCT00348283 [EXTEND]; NCT02365649 [CELEST].
P395 Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s disease
Pai, Rish K. , Reinisch, Walter , Feagan, Brian G. , Agada, Noah , Pollack, P, Chan, Lai Shan, Protić, Marijana , Hertogh, Gert D. , Reinisch, Walter , Harpaz, Noam , Magro, Fernando

Mayo Clinic

Journal of Crohn's and Colitis | May 28, 2021 | Volume: 15 | Issue: Supplement_1 | Pages: S404-S406

10.1093/ecco-jcc/jjab076.519 Get It

Abstract Background Mirikizumab (miri), a p19-directed IL-23 antibody, demonstrated efficacy and was well-tolerated in a phase 2 randomized clinical trial (NCT02891226) in patients with Crohn’s disease (CD). The histologic results at Week (W)12 induction and W52 maintenance are presented here. Methods Patients were randomized 2:1:1:2 across 4 treatment arms (PBO, 200, 600, 1000mg miri) administered intravenously (IV) every four weeks (Q4W) at Weeks 0, 4, and 8. Patients who received miri and achieved ≥1 point improvement from baseline (BL) at W12 in Simple Endoscopic Score for Crohn’s Disease (SES-CD) were re-randomized 1:1 into double-blind maintenance to continue their IV dose assignment Q4W (IV/IV) or to 300mg miri SC Q4W (IV/SC); maintenance IV arms were pooled for analysis. W12 non-improvers and all induction PBO patients received 1000mg miri Q4W from W12 through W52. Biopsies from terminal ileum and 4 colonic segments (ascending, transverse, descending, rectum) were obtained during endoscopy at W0, 12 and 52 and scored blind to treatment and response status. Ileum and colon scores were reported separately. Colon scores were derived from the sum of the 4 colonic segments, and total intestine scores from the 4 colonic segments plus ileum. Endpoints were defined post-hoc but prior to performing the analyses and only included patients with active histologic disease at BL (see Table). Histologic response was defined as: a) absence of neutrophils in lamina epithelialis, and absence of epithelial damage, erosions and ulceration or b) decrease of either RHI or GHAS ≥50% from BL. Histologic remission was defined as absence of mucosal neutrophils, epithelial damage, erosions, and ulceration. Deep histologic remission was defined as histologic remission combined with absence of chronic inflammatory cell infiltration of the lamina propria. For assessment of total intestine inflammation, the criteria for response, remission or deep remission must have been met in all 5 bowel segments. Results At W12, histologic response and remission were significantly higher in all segments of the 1000mg group versus PBO (response: ileum p<0.01, total intestine p<0.01, colon p<0.05; remission: ileum p<0.05, colon p<0.05, total intestine p<0.01). Among the W12 improvers, both histologic response and histologic remission at W52 were similar in ileum and colon in the IV/IV group, but lower in ileum than colon in the IV/SC group. All but 2 patients with remission at W52 were in deep histologic remission. Conclusion Patients treated with miri achieved and sustained histologic response and remission over 52 weeks of treatment. Among patients with W52 histologic remission, all but 2 patients achieved deep remission.